A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor
Status:
Active, not recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase 1 open-label, dose-escalation, safety and pharmacokinetic study of rucaparib
administered twice daily (BID) to Japanese patients with a solid tumor who have failed
previous standard treatment for their cancer. A recommended dose of rucaparib for Japanese
patients will be determined in a dose-escalation portion and then further evaluated in a
dose-expansion portion of the study.